196 related articles for article (PubMed ID: 12490769)
1. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.
Ferguson JM; Wesnes KA; Schwartz GE
Int Clin Psychopharmacol; 2003 Jan; 18(1):9-14. PubMed ID: 12490769
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
3. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
5. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Harmer CJ; Shelley NC; Cowen PJ; Goodwin GM
Am J Psychiatry; 2004 Jul; 161(7):1256-63. PubMed ID: 15229059
[TBL] [Abstract][Full Text] [Related]
6. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
7. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
Ferguson JM; Mendels J; Schwart GE
Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
[TBL] [Abstract][Full Text] [Related]
8. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
9. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
[TBL] [Abstract][Full Text] [Related]
11. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
Eyding D; Lelgemann M; Grouven U; Härter M; Kromp M; Kaiser T; Kerekes MF; Gerken M; Wieseler B
BMJ; 2010 Oct; 341():c4737. PubMed ID: 20940209
[TBL] [Abstract][Full Text] [Related]
12. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
13. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
14. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
[TBL] [Abstract][Full Text] [Related]
15. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
Dobkin RD; Menza M; Bienfait KL; Gara M; Marin H; Mark MH; Dicke A; Tröster A
J Neuropsychiatry Clin Neurosci; 2010; 22(2):188-95. PubMed ID: 20463113
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
17. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.
Moeller O; Hetzel G; Rothermundt M; Michael N; Nyhuis PW; Suslow T; Arolt V; Erfurth A
J Psychiatr Res; 2003; 37(3):261-2. PubMed ID: 12650745
[No Abstract] [Full Text] [Related]
18. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects.
Loubinoux I; Pariente J; Rascol O; Celsis P; Chollet F
Neuropsychologia; 2002; 40(11):1815-21. PubMed ID: 12062893
[TBL] [Abstract][Full Text] [Related]
19. Cognitive effects of paroxetine in older depressed patients.
Nebes RD; Pollock BG; Mulsant BH; Butters MA; Zmuda MD; Reynolds CF
J Clin Psychiatry; 1999; 60 Suppl 20():26-9. PubMed ID: 10513855
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
Eker SS; Akkaya C; Akgöz S; Sarandöl A; Kirli S
Turk Psikiyatri Derg; 2005; 16(3):153-63. PubMed ID: 16180148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
